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Summary
High expression of the ATP-binding cassette-multi-drug efflux protein 1 
(MDR1) is a striking feature of mucosal-associated invariant T (MAIT) 
cells, a prominent human innate-like T cell subset. We demonstrate sig-
nificantly higher MDR1 expression by CD8+CD161++Vα7.2+ MAIT cells 
than the phenotypically and functionally related CD8+CD161++Vα7.2-
subset and show MDR1 expression to be similarly high throughout MAIT 
CD4+, CD8+, double-negative (DN) and double-positive (DP) cell subsets. 
We demonstrate the MAIT cell-predominant CD8+CD161++ subset to 
uniquely and efficiently efflux the cytotoxic anthracycline daunorubicin, 
retain function on daunorubicin exposure and demonstrate MDR1-de-
pendent protection from daunorubicin-induced apoptosis. By contrast, 
CD8+CD161++Vα7.2+ MAIT cells were not protected from the anti-pro-
liferative and cytotoxic effects of the immunosuppressive MDR1 substrates 
tacrolimus and mycophenoic acid, although function following MAIT 
cell-specific T cell receptor (TCR)-dependent and -independent stimulation 
was preserved on in-vitro exposure to these agents. Overall, our data fur-
ther define MDR1 expression by CD161++ T and MAIT cells and dem-
onstrate the potential for high MDR1 expression by MAIT cells to confer 
resistance to cytotoxic MDR1 substrates in vivo. As our understanding of 
the importance of MAIT cells in human immunity and immunopathology 
grows, this is an important observation for clinical contexts such as the 
treatment of malignancy, autoimmunity and post-transplant 
immunosuppression. 
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Introduction
Mucosal-associated invariant T (MAIT) cells are an abun-
dant human innate-like T cell subset. Representing 5–10% 
of peripheral T cells, MAIT cells are enriched within a 
number of tissues, most notably the liver, where they 
account for up to 50% of intrahepatic T cells [1]. MAIT 
cells in humans express a semi-invariant αβ T cell recep-
tor (TCR) and the V-alpha chain Vα7.2 joins to restricted 
Jα segments (Jα33/12/20) and V-beta chains (Vβ2 and 
13.2) [2,3]. The MAIT T cell receptor (TCR) is restricted 
by the highly conserved major histocompatibility complex 
(MHC) class I-like molecule MR1 presenting metabolic 
products of the riboflavin synthesis pathways (derived from 
bacteria and yeasts) [4‒6]. MAIT cells are characterized 
further by expression of the transcription factors retinoic 
acid-related orphan receptor gamma T (RORγt), which 
drives type 17 function and phenotype [CD161, interleukin 
(IL)-23R and chemokine receptor 6 (CCR6) expression] 
and promyelocytic leukaemia zinc finger (PLZF), related 
to their ‘innate’ characteristics including responsiveness 
to IL-18 in synergy with IL-12/IL-15 and type I interferons 
(IFNS) [6,7], MAIT cells are not only phenotypically dis-
tinct, but also multi-functional – primed to respond innately 
to a variety of bacteria, yeast and viruses.
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MAIT cells are contained entirely within the 
CD3+CD161++ population, and the majority of 
CD161++Vα7.2+ MAIT cells are either CD8+CD4– (82.9%) 
or double-negative (DN) CD8–CD4– (12·1%), with a small 
minority of CD8–CD4+ and double-positive (DP) 
CD8+CD4+ [8,9]. There is little functional difference 
between the CD8+CD4–, CD8–CD4+ and DN CD8–CD4– 
CD161++Vα7.2+ populations (although the DN population 
has a greater tendency to apoptosis); however, the CD8–
CD4+CD161++Vα7.2+ subpopulation has reduced T helper 
1 effector function but retained T helper 2 function [8]. 
Further to this, we have previously shown the origins of 
CD8+CD161++Vα7.2+ MAIT cells from the CD8+CD161++ 
subset within cord blood and demonstrated 
CD8+CD161++Vα7.2+ MAIT cells to make up 87% of the 
CD8+CD161++ T cell subset in adults [9].
MDR1 (or P-glycoprotein), encoded by ABCB1, is the 
prototypical drug efflux pump that has been described 
to mediate multi-drug resistance in various malignant cells 
[10]. It is a promiscuous transporter with broad specificity 
for a variety of different substrates, including those that 
also inhibit transport, such as cyclosporin A and verapamil 
[11,12]. While much research has been invested in deter-
mining the role of MDR1 in the resistance of malignant 
cells to treatment, less is known about its physiological 
role. Expression is found in various tissues, including the 
gastrointestinal tract, liver, kidney, adrenal cortex, brain 
and testes [13] with this distribution pattern, suggesting 
a role in protection from xenobiotics or endogenous 
metabolites [10]. Expression has also been described in 
leucocytes [14], with a role in secretion of cytokines and 
cytotoxic mediators within these cells being proposed [15].
Among CD8+ T leucocytes MDR1 expression, the associ-
ated ability to efflux the fluorescent MDR1 substrate rho-
damine 123 (Rh123) and in-vitro and in-vivo resistance to 
daunorubicin was shown initially to be restricted to a 
CD8+CD161++IL18Rα++ memory T cell subset [16], resem-
bling but not specifically identified as MAIT cells. A sub-
sequent study then further identified high MDR1 expression 
by CD4–CD161++Vα7.2+ T cells compared to CD4–
CD161+Vα7.2–, CD4–CD161–Vα7.2+ and CD4–CD161–
Vα7.2– subsets, and demonstrated the ability of the 
CD4–CD161++Vα7.2+ subset alone to efflux Rh123. The 
same study also showed preferential survival of CD4–
CD161++Vα7.2+ T cells in patients both during and after 
anthracycline-containing chemotherapy compared to con-
ventional memory cells on ex-vivo analysis [17]. Given that 
MAIT cells have been shown recently to be enriched within 
solid organ malignancies, where they are associated with 
poor prognosis [18‒21] and identified among previously 
unclassified peripheral T cell lymphomas [22], further 
assessment of the effect of exposure to cytotoxic agents 
on MAIT cell survival and function is an important area 
to explore.
A number of immunosuppressive agents used in trans-
plantation medicine and the treatment of autoimmunity 
are also substrates of MDR1 [13], and reports indicate 
the significance of MDR1 expressing mononuclear cells in 
both transplant rejection [23,24] and treatment-resistant 
autoimmunity [25‒27]. MAIT cells are inherently cross-
reactive due to their restriction by the highly evolutionary 
conserved MR1 allowing for alloactivation through the 
presentation of bacterial-derived ligands. Bystander TCR-
independent cytokine-mediated activation of MAIT cells 
may also occur in the context of inflammation and the 
production of MAIT-activating cytokines such as IL-12 
and IL-18. Preferential survival of MAIT cells in the con-
text of immunosuppression might have both beneficial and 
deleterious effects; on one hand, allowing them to play 
an important role in maintenance of immunity and on 
the other hand as mediators of rejection in transplantation 
or of treatment resistant disease in autoimmunity.
To date, published data on the role of MDR1 on MAIT 
cells and MAIT-containing T cell subsets are limited to 
in-vitro studies of anthracyline resistance of the 
CD161++IL18R+MDR1+ T cell subset [16] and the specific 
Rh123 efflux ability of CD4–CD161++Vα7.2+ cells, along 
with ex-vivo analysis demonstrating preferential survival 
of CD4–CD161++Vα7.2+ cells following anthracycline-con-
taining chemotherapy compared to conventional memory 
cells [17]. In this study we further define the expression 
of MDR1 on CD161++ and MAIT T cell subsets. We 
demonstrate the ability of CD8+CD161++ cells to efflux 
the anthracycline daunorubicin efficiently and describe the 
effect of in-vitro exposure to daunorubicin on CD8+CD161++ 
T cell survival and function. Furthermore, we investigate 
for the first time, to our knowledge, the effects of the 
immunosuppressive MDR1 substrates tacrolimus, 
mycophenolic acid (MPA) (the active metabolite of mycyo-
phenolate mofetil) and the corticosteroid prednisolone on 
MAIT cell proliferation, survival and function.
Materials and methods
Cells
Peripheral blood mononuclear cells (PBMC) were obtained 
from whole blood leucocyte cones (NHS Blood and 
Transplant, Watford, UK), after ethical approval by the 
Central Office for Research Ethics Committees (local 
research ethics committee Oxford: COREC), reference 
number COREC 04.OXA.010.
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Flow cytometry
Dead cells were excluded with the Near-IR Dead-Cell stain 
(Invitrogen, Paisley, UK). Antibodies used were: anti-CD3 
phycoerythrin-cyanin7 (PE-Cy7) or allophycocyanin (APC), 
anti-CD8 peridinin chlorophyll (PerCP)-Cy5.5 or eFluor 
450 (eBioscience, Hatfield, UK); anti-CD161 PE or APC, 
anti-CD8 VioGreen, anti-interferon (IFN) fluorescein iso-
thiocyanate (FITC) (Miltenyi Biotec, Surrey, UK); anti-V7.2 
PE or FITC or PECy7, anti-perforin Pacific Blue, anti-
CD243/MDR1 PE (Biolegend, London, UK); anti-granzyme 
B AlexaFluor700, anti-perforin FITC, anti-IFN 
AlexaFluor700 (BD Biosciences, Oxford, UK) and anti-
granzyme B APC (Invitrogen). For intracellular antibody 
staining cells were stained with the forehead box protein 
3 (FoxP3)/transcription factor staining buffer set (eBiosci-
ence, Birmingham, UK).
Data were acquired on a MACSQuant (Miltenyi Biotec) 
or LSRII (BD Bioscience) and analysed using FlowJo 
software version 9 (Treestar, Inc., Ashland, OR, USA).
Daunorubicin efflux assay
Fresh PBMCs were loaded with 2·5  M daunorubicin hydro-
chloride (Sigma, Poole, UK) for 20  min at 37°C and allowed 
to efflux for 1  h. Loading controls were kept on ice. After 
efflux, cells were returned to ice and surface stained for analysis. 
Daunorubicin fluorescence was measured at 610/20  nm on 
the LSRII (BD Biosciences). Efflux was calculated as:
(GeoMFI fluorescent substrate)Loading control (GeoMFI 
 fluorescent substrate)Efflux
(GeoMFI fluorescent substrate)Loading control
Cytotoxicity assay
PBMCs were cultured with various concentrations of 
daunorubicin, tacrolimus, MPA and prednisolone (Sigma) 
and apoptosis detected by intracellular staining for acti-
vated caspase 3 (BD Pharmingen, Wokingham, UK) or 
by annexin V (Miltenyi Biotec) surface staining after 24 
or 48  h, respectively. Annexin V staining was performed 
for 15  min at room temperature in annexin V binding 
buffer (Miltenyi Biotec); 50  M Verapamil (Sigma) was 
added at the beginning of culture. Percentages expressing 
annexin V at each concentration were background sub-
tracted for annexin V expression in media alone.
Proliferation assay
PBMCs were thawed and washed extensively in phosphate-
buffered saline (PBS) before being stained with 2·5  M 
CellTraceTM Violet (CTV) dye (Invitrogen) for 10  min at 
room temperature. Ice-cold medium was added to quench 
the reaction, and cells kept on ice for 5  min. Cells were 
then washed three times in medium, transferring cells into 
new tubes between each wash. Finally, cells were incubated 
at 37°C for 5  min, to allow excess dye to diffuse out. Cells 
were then resuspended at 2 × 106/ml in RPMI-1640 medium 
(Gibco, ThermoFisher Scientific, Waltham, MA, USA), 10% 
normal human serum (Sigma), 2 mM L-glutamine (Gibco) 
and ×1 penicillin–streptomycin solution (Gibco) with anti-
CD3/2/28 activation beads (Miltenyi Biotec), as per the 
manufacturer’s instructions, and cultured in 48-well flat-
bottomed plates with or without immunosuppressants 
tacrolimus, prednisolone or MPA (Sigma). After 4 days, 
cells were split and either surface-stained for analysis of 
CTV dilution or assessed for functional activity.
Tamm–Horsfall protein (THP)-1/Esherichia coli 
stimulation assay
THP-1 cells [European Collection of Authenticated Cell 
Cultures (ECACC), Salisbury, UK] were incubated over-
night with paraformaldehyde-fixed E. coli (DH5; 
Invitrogen) at 25 bacteria per cell. Following culture with 
immunosuppressant drugs tacrolimus, prednisolone or 
MPA, PBMC were washed extensively then added to 
washed THP1s for a 5-h co-culture, with 3 g/ml brefeldin 
A (eBioscience) added after 1  h. IFN production was 
assayed by intracellular cytokine staining.
IL-12/IL-18 stimulation assay
Following culture with immunosuppressant drugs tacroli-
mus, MPA or prednisolone, PBMC were incubated with 
IL-12 (Miltenyi Biotec) and IL-18 (R&D Systems, 
Abingdon, UK), each at 50  ng/ml overnight; 3  μg/ml 
brefeldin A (eBioscience) was added for the final 4  h of 
incubation and IFN-γ production assayed by intracellular 
cytokine staining.
CD3/CD28 bead stimulation assay
For activation through the TCR, PBMC were cultured 
with anti-biotin beads coated with anti-CD2-biotin, 
anti-CD3-biotin and anti-CD28-biotin at 10  μg/ml at a 
bead-to-cell ratio of 1 : 2, according to the T cell Activation/
Expansion kit (Miltenyi Biotec) instructions. IFN-γ pro-
duction was assayed after 24  h by intracellular cytokine 
staining.
Statistical analysis
Statistical analysis, as stated in the figure legends, was 
performed using Prism version 6 software (GraphPad, 
San Diego, CA, USA). Data are represented as 
mean ± standard error of the mean (s.e.m.); ****P < 0·0001, 
***P  <  0·001, **P  <  0·01, *P  <  0·05, n.s.  =  not significant, 
as stated in the figure legends.
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Results
MDR1 expression is similar among MAIT cell subsets 
and MAIT cells express the highest levels of MDR1 
among CD8+ T cells
CD161++CD8+IL-18R+ T cells [16], and specifically CD4-
CD161++Va7.2+ MAIT cells [17], have been described to 
express high levels of the multi-drug efflux pump MDR1. 
Here we demonstrate naive CD161–CD8+ cells to express 
similar levels of MDR1 to CD161+ memory CD8+ T cells, 
and both subsets to express higher levels than their 
CD161+CD8+ memory counterparts. Furthermore, 
CD161++CD8+ T cells, the majority of which were MAIT 
cells [9], expressed significantly higher levels of MDR1 
than all other CD8+ T cell populations, confirming previ-
ous studies (Fig. 1a) (gating strategies are shown in 
Supporting information, Fig. S1a).
Following from our work looking at differential phe-
notypes and functions of MAIT cell subsets [8], we further 
defined MDR1 expression throughout MAIT subsets based 
on CD4 and CD8 co-receptor expression. CD4+ MAITs 
express significantly less MDR1 compared to the DP subset, 
but otherwise no statistically significant difference between 
subsets was observed (Fig. 1b). (see Supporting informa-
tion, Fig. S1b for gating strategy and Supporting informa-
tion Fig. S1c for MAIT subset distribution within our 
data set).
We have shown previously that the effector memory 
CD8+CD161++Vα7.2+ MAIT cell population is derived 
from a pool of naive CD8+CD161++ T cells identified in 
cord blood [9], and for CD8+CD161++Vα7.2- T cells to 
share many important phenotypical and functional char-
acteristics with MAIT cells, including expression of the 
transcription factors PLZF, RORγt and TCR-independent 
activation by IL-12/IL-18 [28]. We therefore compared 
MDR1 expression on the CD8+CD161++Vα7.2+ and 
CD8+CD161++Vα7.2– subsets and demonstrated similarly 
high expression of MDR1 by both CD8+CD161++Vα7.2+ 
MAIT cells and the CD8+CD161++Vα7.2– subset, although 
Fig. 1. Mucosal-associated invariant T (MAIT) cells express high levels of multi-drug resistance protein 1 (MDR1). (a) Cumulative data showing 
geometric mean fluorescent intensity (GeoMFI) of MDR1 by each subset including naive (CCR7+CD45RA+) and memory (excluding CCR7+CD45RA+) 
CD161–CD8+ (red), CD161+CD8+ (blue) and CD161++CD8+ (green) subsets (n = 15). ***P < 0·001; **P < 0018301; n.s. = not significant by one-way 
analysis of variance (anova) with Tukey’s multiple comparisons test. Data are represented as mean  ±  standard error of the mean (s.e.m.). (b) 
Cumulative data showing GeoMFI of MDR1 by each CD3+CD161++Vα7.2+ subset including CD4+ (red), CD8+ (blue), double-negative (DN)/CD4–
CD8– (green) and double-positive (DP)/CD4+CD8+ subsets (orange) (n = 5). *P < 0.05; n.s. = non-significant by Kruskal–Wallis with Dunn’s multiple 
comparison test. (c) Representative flow cytometry data of MDR1 expression by CD161++CD8+ subsets, either Vα7.2+ (green dotted line) or Vα7.2– 
(green solid line), compared to the fluorescence minus one (staining control) sample (grey). (d) Paired data for geometric mean fluorescent intensity 
(GeoMFI) of MDR1 by CD161++CD8+Vα7.2+ and CD161++CD8+Vα7.2– T cells. *P  <  0·05 by paired t-test.
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MDR1 expression was significantly higher on 
CD8+CD161++Vα7.2+ MAIT cells compared to the 
CD8+CD161++Vα7.2– subset (Fig. 1c).
MAIT cells are protected from cytotoxicity during 
exposure to daunorubicin
We have previously proved the functional activity of MDR1 
on CD8+CD161++ cells using the fluorescent substrate Rh123 
and demonstrated inhibition by the MDR1 inhibitors cyclo-
sporin A and verapamil [29]. While efflux was not as 
marked as for Rh123, the CD8+CD161++ T cells were able 
to efflux the fluorescent anthracycline daunorubicin signifi-
cantly more efficiently than other CD8+ T cell subsets, both 
CD8+CD161+ (P < 0·01) and CD8+CD161– (P < 0·001) (Fig. 
2a,b). Further to this, we demonstrate that the CD8+CD161++ 
subset is able to efflux daunorubicin significantly more 
efficiently than the CD8–CD161++ subset (Fig. 2c), which 
may be accounted for by different levels of MDR1 expres-
sion (see Fig. 1d) and may add to the greater apoptotic 
tendency of the DN MAIT cell subset [8].
It has been demonstrated previously that CD4–
CD161++Vα7.2+ MAIT cells have a superior ability to 
survive anthracycline-containing chemotherapy in patients 
undergoing treatment for breast cancer compared to other 
T cell subsets [17]. We determined the ability of 
CD8+CD161++ cells (which are predominantly Vα7.2+ 
MAIT cells) to survive exposure to anthracycline prefer-
entially by culture of PBMCs with daunorubicin for 48  h, 
with apoptosis evaluated by annexin V staining. When 
CD8+ T cells were gated based on the level of CD161 
expression, CD161++CD8+ T cells were found to be sig-
nificantly more resistant to daunorubicin-induced apop-
tosis at concentrations of 0·5–10  μM/l compared to the 
other CD8+ T cell subsets (Fig. 2d,e). Such protection 
was attributable to their expression of MDR1, as resist-
ance was abrogated by addition of the MDR1 inhibitor 
verapamil, determined by staining for activated caspase 
3, an additional marker of apoptosis (Fig. 2f,g).
In addition to resisting cytotoxic effects, we next inves-
tigated whether CD8+CD161++ cells remained functional 
after exposure to daunorubicin by co-culture of dauno-
rubicin-exposed PBMCs with Escherichia coli-pulsed 
THP1s, shown previously to specifically activate the MAIT 
cell subset [6,27]. While CD8+CD161++ cells retained the 
ability to respond, the percentage of live cells producing 
IFN-γ in response to E. coli was reduced upon culture 
with daunorubicin, particularly at a concentration of 
10  μM, where the response was reduced significantly by 
more than 40% (mean 79·65 versus 46·10%). A smaller 
reduction in function was also observed at lower con-
centrations (Fig. 2h).
MAIT cells are susceptible to immunosuppressant 
MDR1 substrates but remain functional after in-vitro 
exposure
The ability of CD161++CD8+ T cells to survive culture 
with chemotherapeutic agents through drug efflux suggests 
that they may also possess the ability to efflux, and hence 
be resistant to, other pharmacological MDR1 substrates. 
We therefore investigated the ability of 
CD8+CD161++Vα7.2+ MAIT cells to withstand the effects 
of the immunosuppressant MDR1 substrates tacrolimus, 
MPA and prednisolone.
We first examined the effect of tacrolimus, MPA and 
prednisolone on CD8+CD161++Vα7.2+ MAIT cell prolifera-
tion, assayed by CTV dilution, upon anti-CD3/CD2/CD28 
stimulation for 4 days (Fig. 3a) in the presence or absence 
of physiological concentrations of tacrolimus (Fig. 3b), MPA 
(Fig. 3c) or prednisolone (Fig. 3d). The percentage of cells 
that had proliferated was determined by identifying cells 
that had lost CTV fluorescence (CVTlo), representing daugh-
ter cells. In the absence of drugs, both CD8+CD161++Vα7.2+ 
MAIT cells and bulk (non-MAIT) CD8+ T cells proliferated 
in response to TCR stimulation (Fig. 3a). However, both 
subsets were inhibited similarly by tacrolimus and MPA 
at all concentrations of drugs used in the assay (Fig. 3b,c). 
By contrast, both CD8+CD161++Vα7.2+ MAIT and bulk 
(non-MAIT) CD8+ T cell proliferation remained uninhibited 
in the presence of prednisolone at the concentrations used 
(Fig. 3d). Levels of MAIT cell apoptosis, as measured by 
annexin V staining, following 4 days’ culture with various 
concentrations of tacrolimus, MPA and prednisolone, was 
not significantly different from cells cultured in media alone 
(Supporting information Fig. S2a).
We next explored the effect of co-culture with tacroli-
mus, MPA and prednisolone on CD8+CD161++Vα7.2+ 
MAIT cell TCR-dependent and -independent functions. 
MAIT cells retained their ability to produce IFN-γ on 
stimulation by both E. coli-loaded THP1 cells at similar 
levels to untreated cells (Supporting information, Fig. S3a). 
Response was affected non-significantly by a combination 
of all three drugs (Supporting information, Fig. S2b).
MAIT cells have also been described to respond to the 
combination of IL-12 and IL-18 in a TCR-independent 
manner [7]. This response was also maintained after expo-
sure to all three drugs, among all drug concentrations 
tested (Supporting information, Fig. S3b). As both these 
assays activate MAIT cells specifically, no direct comparison 
with the effect on function of non-MAIT T cells could 
be made in these experiments.
In the resting state, MAIT cells lack granzyme B and 
express low levels of perforin, but have been shown to 
up-regulate these molecules upon activation to enable 
J. R. Fergusson et al.
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cytotoxicity against target cells [30]. We therefore explored 
the effect of 4 days’ pre-culture with tacrolimus, MPA 
and prednisolone on up-regulation of perforin and gran-
zyme B by CD8+CD161++Vα7.2+ MAIT cells following 
stimulation with anti-CD3/CD2/CD28 beads. Untreated 
cells showed substantial up-regulation of both cytotoxic 
mediators after activation, which was inhibited significantly 
throughout all concentrations of tacrolimus and MPA 
tested, but not following exposure to prednisolone 
(Fig. 4a,b), reflecting proliferative responses (Fig. 3).
Discussion
Interest in and evidence for the significance of MAIT 
cells to human immunity is building  –  not least in terms 
of their prevalence, location at key sites of pathogen entry 
and conserved innate multi-functionality against bacterial, 
fungal and viral infections. Many clinical studies have 
indicated involvement of MAIT cells in the context of 
infection, and a role in autoimmunity and malignancy is 
also emerging (reviewed in [1]). Markedly high expression 
of MDR1 specifically by MAIT cells is demonstrated clearly 
by our data, with similar expression among all MAIT 
subsets. Their resistance to the effects of anthracyline 
cytotoxic MDR1 substrates is a significant observation 
and important to consider in the clinical contexts of solid 
organ and haematological malignancy. Furthermore, MAIT 
cell susceptibility to the anti-proliferative and cytotoxic 
effects of the immunosuppressive agents tacrolimus and 
MPA has important implications for related research in 
the fields of autoimmunity and transplantation and a role 
in driving immunosuppression resistant disease/rejection, 
as hypothesized, less likely.
There are few studies of the role of MAIT cells in malig-
nancy, but their accumulation has been demonstrated in 
kidney and brain cancer [19], with the degree of MAIT 
cell infiltration and activation correlating negatively with 
life expectancy in colorectal adenocarcinoma [18,20,21]. In 
addition, MAIT cells have been described to account for 
a significant proportion of previously unclassified peripheral 
T cell lymphomas [22]. Our data, in keeping with previous 
studies [16,17], further demonstrate MAIT cells to prefer-
entially survive exposure to cytotoxic MDR1 substrates. We 
show not only a significantly greater efflux of daunorubicin 
from MAIT cells compared to other cell subsets, in line 
with data showing efflux by effector memory CD161++CD8+ 
T cells [16], but also directly demonstrate MDR1-mediated 
protection from apoptosis for the first time, previously cor-
related only with preferential survival in patients receiving 
chemotherapy for breast cancer over other lymphocyte 
subsets [17]. Furthermore, we show daunorubicin exposed 
MAIT cells maintain, albeit reduced, function following 
physiological MR1-mediated stimulation through the MAIT 
cell TCR. All experiments, however, were conducted with 
MAIT cells exposed to daunorubicin in a quiescent state. 
It would be interesting to know if the same protection is 
afforded to cells activated prior to drug exposure.
At this stage it is difficult to interpret the negative 
correlations between MAIT cell infiltration, tumour biol-
ogy and life expectancy. Whether infiltration by high 
numbers of MAIT cells is important for anti-cancer 
immunity and a correlate of an aggressive tumour or 
whether they contribute directly to tumour growth, for 
example by IL-17-mediated recruitment of suppressive 
neutrophils and myeloid-derived suppressor cells, is not 
known and may differ between individual malignancies. 
However, given our findings, further studies of the role 
of MAIT cells in malignancy will have important implica-
tions for cancer therapy, including better understanding 
of their survival and susceptibility to chemotherapeutic 
Fig. 2. Mucosal-associated invariant T (MAIT) cells are protected from cytotoxicity during exposure to daunorubicin. (a) Representative flow cytometry 
data of peripheral blood mononuclear cells (PBMC) loaded with daunorubicin and cultured on ice (loading control; left) or at 37°C (efflux; right) and 
gated on CD8+CD3+ lymphocytes. (b) Cumulative data for daunorubicin efflux by each CD8+ T cell subset calculated as per materials and methods 
(n = 6). ***P < 0·001; **P < 0·01; *P < 0·05; n.s. = not significant by one-way analysis of variance (anova) with Tukey’s multiple comparisons test. Data 
are represented as mean ± standard error of the mean (s.e.m.). (c) Cumulative data for duanorubicin efflux by CD8+CD161++ and CD8–CD161++ 
subsets calculated as per materials and methods (n = 6). *P < 0·05 by Mann–Whitney test. Data are represented as mean ± s.e.m. (d) Representative flow 
cytometry plots of annexin V staining of PBMC cultured for 48  h in media alone or with various concentrations of daunorubicin, and gated on 
CD8+CD3+ lymphocytes. (e) Cumulative data for percentage of CD161– (red), CD161+ (blue) and CD161++ (green) CD8+ T cells stained by annexin V 
after culture for 48 h with various concentrations of daunorubicin. ***P < 0.001; **P < 0.01; *P < 0.05; n.s. = not significant by one-way anova with 
Tukey’s multiple comparisons test; all other comparisons were not significant. Data are represented as mean ± s.e.m. (f) Representative flow cytometry 
plots of caspase 3 expression in CD8+CD3+ lymphocytes from PBMC after culture with media alone or 1 μM daunorubicin, with or without the MDR1 
inhibitor verapamil (50 μM), for 48 h. Cells cultured with verapamil alone are also shown. (g) Cumulative data for percentage of each subset, expressing 
caspase 3 after culture with daunorubicin alone (block colour) or with verapamil (hatched bars) (n = 5). Data are represented as mean ± s.e.m. (h) 
Cumulative data for percentage of MAIT cells expressing interferon (IFN)-γ in response to Escherichia coli-loaded Tamm–Horsfall protein (THP)1 
cells after 48 h culture in the presence of various concentrations of daunorubicin (n = 6). ***P < 0·001, *P < 0·05, n.s. = not significant by one-way 
anova with Dunnett’s multiple comparison test, compared to untreated cells. Data are represented as mean ± standard error of the mean (s.e.m.).
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agents and in the potential use of MAIT cell-targeting 
depletive or adoptive transfer therapy.
Potential pathogenic and protective roles of MAIT cells 
are described in autoimmune disease from both clinical 
and murine studies published in multiple sclerosis (MS), 
rheumatoid arthritis (RA), systemic lupus (SLE), ankylos-
ing spondylitis, inflammatory bowel disease (IBD) and 
coeliac disease (reviewed in [31]). Accumulation of MAIT 
Fig. 3. Mucosal-associated invariant T (MAIT) cells are susceptible to the anti-proliferative effects of tacrolimus and mycophenolic acid (MPA). (a) 
Representative flow cytometry plots showing CellTraceTM Violet (CTV) dilution upon proliferation of CD3+ lymphocytes, non-MAIT bulk CD8+ T 
cells (CD3+CD8+ lymphocytes, excluding CD161++Vα7.2+) or MAIT cells (CD3+CD8+CD161++Vα7.2+) after activation with anti-CD3/CD2/CD28 
beads for 4 days. Representative flow cytometry plots and cumulative data for the percentage of either MAIT (green) or non-MAIT bulk CD8+ T cells 
(orange hatch) proliferated (CTVlo) after 4 days’ culture with anti-CD3/CD2/CD28 beads are shown for cells cultured in the presence of either 
tacrolimus (b), MPA (c) and prednisolone (d). Representative flow cytometry plots are shown for the middle concentration of each drug, namely 10 ng/
ml tacrolimus, MPA 4 mg/ml and prednisolone 50 ng/ml. Gates were set according to unstimulated controls (n = 6).
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cells at sites of tissue inflammation, including inflamma-
tory lesions in MS [32‒34], the gut in IBD [35,36] and 
synovial fluid in RA [37], suggests a pathogenic role. 
However, in the murine model of MS, experimental auto-
immune encephalitis (EAE), in both adoptive transfer and 
transgenic studies, MAIT cells protected against central 
nervous system (CNS) inflammation and demyelination 
and MR1–/– mice, which lack MAIT cells, suffered more 
severe EAE [38]. There have been no studies of MAIT 
cells in rejection of solid organ transplantation. There 
have been conflicting reports on the role of CD161+ and 
CCR6+ lymphocyte subsets, not formally defined as con-
taining MAIT cells, in graft-versus-host disease (GVHD) 
following bone marrow or haematopoetic stem cell trans-
plantation preceded by myeloablative conditioning [inter-
estingly, MAIT cells do not re-emerge post-transplant 
following non-myeloablative conditioning with anti-CD52 
therapy [39] (L. J. Walker, unpublished data) ]. These 
studies suggest both protective [40] and pathogenic roles, 
along with protection of CD161+CCR6+ cells from the 
anti-proliferative effects of cyclosporin A within a mixed 
leucocyte reaction (MLR) model [41]. Alloactivation of 
MAIT cells due to their inherent cross-reactivity via a 
TCR restricted to the highly evolutionarily conserved MR1 
would require the presentation of bacterial antigen in the 
context of infection or contamination; however, bystander 
TCR-independent activation may occur in an inflamma-
tory environment and play a role in mediation and aug-
mentation of rejection or organ dysfunction 
post-transplant. For example, IL-18 is a key activator of 
MAIT cells in synergy with other proinflammatory 
cytokines and has been implicated in both delayed liver 
graft function in a rat model [42] and episodes of liver 
transplant rejection in humans [43]. A role of MAIT 
cells in this setting (especially in the liver, where they 
are an abundant lymphocyte subset) has not been explored 
but would be an important area for further study.
Our data suggest that, as with daunorubicin, the MAIT 
cell responses to TCR-dependent and -independent stimuli 
are preserved following exposure to the MDR1 substrates 
tacrolimus, MPA and prednisolone. However, MAIT cell 
expression of the cytotoxic molecules, granzyme B and 
perforin, and proliferation upon anti-CD3/CD2/CD28 bead 
stimulation was inhibited similarly as in non-MAIT cells 
following exposure to tacrolimus and MPA, and therefore 
no MDR1-related protective effect was demonstrated. This 
suggests relative immunosuppression in the context of 
such drug treatment and may have a significant effect in 
terms of protective MAIT cell effector function and also 
unwanted autoimmunity and rejection. Prednisolone failed 
to inhibit proliferation of both MAIT and non-MAIT 
cell subsets in this model, and MAIT cell cytotoxicity 
was also preserved. Previous data have demonstrated the 
suppressive effects of fluticasone and budesonide in vitro 
on MAIT cells using monocyte derived macrophages 
(MDM) co-cultured with Haemophilus influenzae (HI). 
However, in these experiments the steroids were added 
upon co-culture of the MDMs with the HI and they also 
demonstrated down-regulation of MR1 surface expression, 
indicating an immunosuppressive effect on the mac-
rophages rather than the MAIT cells specifically [44]. In 
our experiments the immunosuppressive drugs were only 
added after overnight co-culture of fixed E. coli with 
THP-1 cells and so it is less likely that MR1 expression 
would have been affected, which may account for the 
differences in results. Overall, such preserved function 
may allow for some preservation of MAIT function in 
the context of immunosuppression, which may either be 
Fig. 4. Up-regulation of cytotoxic mediators is inhibited in mucosal-associated invariant T (MAIT) cells exposed to tacrolimus and mycophenolic acid 
(MPA). Cumulative data for fold up-regulation of perforin (a) and granzyme B (b) by CD8+CD161++Vα7.2+ MAIT cells relative to unstimulated 
controls after stimulation with anti-CD3/CD2/CD28 beads for 24  h, following 4 days culture with various concentrations of tacrolimus, MPA or 
prednisolone (n = 5). *P < 0·05; n.s. = not significant by one-way analysis of variance (anova) with Dunnett’s multiple comparison test, compared to 
untreated cells. Data are represented as mean ± standard error of the mean (s.e.m.).
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important in maintaining protective immunity or allow 
for unwanted immunosuppression-resistant inflammation, 
but the observation of the Hinks study is important  –  as 
the effect of drugs on the immune system must be addressed 
in the context of all players and not just one cell type. 
However, in view of these conflicting data [41,44], further 
analysis is needed using other immunosuppressive MDR1 
substrates. If MAIT cells are shown to have a role in 
the pathogenesis of autoimmunity or transplant rejection 
and GVHD, these varying results would suggest that tai-
lored therapeutic approaches may be required.
In this study we have further defined MDR1 expression 
by MAIT and CD161++ subsets and explored the effect 
of exposure of MAIT cells to both cytotoxic and immu-
nosuppressive MDR1 substrates. Our data demonstrate 
not only that MAIT cells survive exposure to cytotoxic 
agents in an MDR1-dependent manner, but also remain 
functional. High MDR1 expression by MAIT cells is strik-
ing among lymphocytes and further understanding of its 
physiological role and the implications of this within the 
clinical settings of malignancy, autoimmunity and trans-
plantation is clearly required.
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Fig. S1. (a) Gating strategy shown for analysis of fluo-
rescence activated cell sorter (FACS) plots for Fig. 1a. 
(b) Gating strategy shown for analysis of FACS plots for 
Fig. 1b–d. (c) Collated data showing subset distribution 
for the CD161++Va7.2+ population.
Fig. S2. Mucosal-associated invariant T (MAIT) cell survival 
in culture is not affected by exposure to tacrolimus, 
mycophenolic acid (MPA) or prednisolone, and function 
is maintained after culture with a drug combination. (a) 
After culture with various concentrations of tacrolimus, 
MPA and prednisolone for 4 days, cells were stained with 
annexin V. Cumulative data for percentage of MAIT cells 
that were annexin V-positive (n = 6); n.s. = not significant 
by one-way analysis of variance (anova) with Dunnett’s 
multiple comparison test, compared to untreated cells. Data 
are represented as mean  ±  standard error of the mean 
(s.e.m.). (b) After culture with a mixture of 10  ng/ml 
tacrolimus, 4  g/ml MPA and 50  ng/ml prednisolone for 
4 days, cells were removed and incubated for 5  h with 
Escherichia coli-loaded Tamm–Horsfall proteins (THP1s). 
Cumulative data for percentage of MAIT cells expressing 
interferon (IFN)-γ in response (n  =  3); n.s.  =  not signifi-
cant by paired t-test. Data are represented as mean ± stand-
ard error of the mean (s.e.m.).
Fig. S3. Mucosal-associated invariant T (MAIT) cells retain 
function after exposure to tacrolimus, mycophenolic acid 
(MPA) and prednisolone following physiological T cell 
receptor (TCR)-dependent and -independent stimulation. 
Cumulative data of percentage of MAIT cells producing 
interferon (IFN)-γ after (a) 5 h co-culture with Escherichia 
coli-loaded Tamm–Horsfall proteins (THP1s) and (b) 
overnight incubation with interleukin (IL)-12 and IL-18 
following 4 days culture in the presence of media alone 
or various concentrations of tacrolimus, MPA and pred-
nisolone (n = 6); n.s. = not significant by one-way analysis 
of variance (anova) with Dunnett’s multiple comparison 
test, compared to untreated cells. Data are represented 
as mean  ±  standard error of the mean (s.e.m.).
